Approaching 65 Years: Is It Time to Consider Retirement of Vancomycin for Treating Methicillin-Resistant Staphylococcus aureus Endovascular Infections?

Vancomycin was introduced nearly 65 years ago and remains the standard antibiotic for serious methicillin-resistant Staphylococcus aureus (MRSA) infections. Staphylococcus aureus remains highly susceptibility to vancomycin (>97%). Despite this, MRSA treatment failure with vancomycin is high in co...

Descripción completa

Detalles Bibliográficos
Autores principales: Rose, Warren, Volk, Cecilia, Dilworth, Thomas J, Sakoulas, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043000/
https://www.ncbi.nlm.nih.gov/pubmed/35493116
http://dx.doi.org/10.1093/ofid/ofac137

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043000/
https://www.ncbi.nlm.nih.gov/pubmed/35493116
http://dx.doi.org/10.1093/ofid/ofac137

Ejemplares similares